|Bid||2.3900 x 2200|
|Ask||2.4300 x 4000|
|Day's range||2.3500 - 2.4650|
|52-week range||2.1200 - 13.6800|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The stock market was experiencing a frothy Friday on the last trading day of the week, but 23andMe Holding (NASDAQ: ME) was a bit of a wallflower at the party. As of 1:30 p.m. ET , the genetic testing and research specialist's shares were up only incrementally, at a rate well behind the S&P 500 index's 1.7% gain. For 23andMe's fourth quarter of fiscal 2022, the company recorded just under $101 million in revenue, which was 14% higher than the same period of the previous year.
Investing in stocks comes with the risk that the share price will fall. And unfortunately for 23andMe Holding Co...
In this podcast, Motley Fool contributor Brian Orelli interviews Anne Wojcicki, the CEO of 23andMe (NASDAQ: ME), about her company and why it's looking to tell you much more than the names of your long-lost relatives. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Anne Wojcicki: [MUSIC] When I think one of our legacies, hopefully, will be, is that 23andme has really proven that complicated information can go direct to a consumer, it does not have to have a one-to-one interaction with the physician.